NCT04763226View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

April 14, 2021

Primary Completion Date

February 27, 2022

Study Completion Date

February 27, 2022

Conditions
Healthy Participants
Interventions
DRUG

BMS-986308

Specified dose on specified days

OTHER

Placebo (for BMS-986308)

Specified dose on specified days

DRUG

Furosemide

Specified dose on specified days

Trial Locations (1)

66219

Local Institution - 0001, Lenexa

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY